싱가포르 - 영어 - HSA (Health Sciences Authority)

fresenius kabi (singapore) pte ltd - poly (o-2-hydroxyethyl) starch; sodium chloride - injection - 60 g/l - poly (o-2-hydroxyethyl) starch 60 g/l; sodium chloride 9 g/l

몰타 - 영어 - Medicines Authority

fresenius kabi limited - poly(o-2-hydroxyethyl)starch; potassium chloride; magnesium chloride hexahydrate; sodium acetate trihydrate; sodium chloride - solution for infusion - poly(o-2-hydroxyethyl)starch 60 g; potassium chloride 0.3 g; magnesium chloride hexahydrate 0.3 g; sodium acetate trihydrate 4.63 g; sodium chloride 6.02 g - blood substitutes and perfusion solutions

미국 - 영어 - NLM (National Library of Medicine)

fresenius kabi usa, llc - mitoxantrone hydrochloride (unii: u6usw86rd0) (mitoxantrone - unii:bz114nvm5p) - mitoxantrone 2 mg in 1 ml - mitoxantrone injection, usp is indicated for reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses). mitoxantrone injection, usp is not indicated in the treatment of patients with primary progressive multiple sclerosis. the clinical patterns of multiple sclerosis in the studies were characterized as follows: secondary progressive and progressive relapsing disease were characterized by gradual increasing disability with or without superimposed clinical relapses, and worsening relapsing-remitting disease was characterized by clinical relapses resulting in a step-wise worsening of disability.  mitoxantrone injection, usp in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. mi

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - metronidazole, quantity: 500 mg - injection, solution - excipient ingredients: water for injections; citric acid; sodium chloride; dibasic sodium phosphate - metronidazole juno is indicated for:treatment of severe anaerobic infection when oral medication is not possible or is contraindicated, when immediate anti-anaerobic therapy is required. metronidazole may be used prophylactically to prevent infection of the surgical site which may have been contaminated or potentially contaminated with anaerobic organisms. procedures in which this may be assumed to have happened include appendectomy, colonic surgery, vaginal hysterectomy, abdominal surgery in the presence of anaerobes in the peritoneal cavity and surgery performed in the presence of anaerobic septicaemia.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - amoxicillin sodium, quantity: 530.1 mg (equivalent: amoxicillin, qty 500 mg); potassium clavulanate, quantity: 119.2 mg (equivalent: clavulanic acid, qty 100 mg) - injection, powder for - excipient ingredients: - curam is an antibiotic alternative to narrow spectrum and broad-spectrum antibiotics for the treatment of polymicrobial infections; especially in mixed gram negative and gram positive infections, and situations where microbial confirmation has not yet been obtained.,infections caused by amoxicillin susceptible organisms are amenable to curam treatment due to its amoxicillin content.,infections caused by beta-lactamase producing amoxicillin resistant organisms are also amenable to curam due to its clavulanic acid content.,susceptibility to curam will vary with geography and time. local susceptibility data should be consulted where available, and microbiological sampling and susceptibility testing performed where necessary. amoxicillin/clavulanic acid should be used in accordance with local official antibiotic-prescribing guidelines and local susceptibility data.,curam is indicated for the short term treatment of serious bacterial infections such as:,? upper respiratory tract infections (including ent): e.g. mastoiditis, tonsillitis, otitis media, epiglotitis and sinusitis when accompanied by severe signs and symptoms,? lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar, broncho-pneumonia and community acquired pneumonia,? genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections,? gastrointestinal infections e.g. intra-abdominal sepsis, peritonitis.,? skin and skin structure infections, in particular cellulitis, animal bites, diabetic foot infections, vascular surgery infection/ischaemic soft tissue infection, severe dental abscess,? other infections e.g. septic abortion, puerperal sepsis, post-surgical infections.,? curam is indicated for prophylaxis against infection in major surgical procedures that may be associated with higher risk of infectious complications eg. gastrointestinal surgery.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - amoxicillin sodium, quantity: 1.06 g (equivalent: amoxicillin, qty 1 g); potassium clavulanate, quantity: 238.3 mg (equivalent: clavulanic acid, qty 200 mg) - injection, powder for - excipient ingredients: - curam is an antibiotic alternative to narrow spectrum and broad-spectrum antibiotics for the treatment of polymicrobial infections; especially in mixed gram negative and gram positive infections, and situations where microbial confirmation has not yet been obtained.,infections caused by amoxicillin susceptible organisms are amenable to curam treatment due to its amoxicillin content.,infections caused by beta-lactamase producing amoxicillin resistant organisms are also amenable to curam due to its clavulanic acid content.,susceptibility to curam will vary with geography and time. local susceptibility data should be consulted where available, and microbiological sampling and susceptibility testing performed where necessary. amoxicillin/clavulanic acid should be used in accordance with local official antibiotic-prescribing guidelines and local susceptibility data.,curam is indicated for the short term treatment of serious bacterial infections such as:,? upper respiratory tract infections (including ent): e.g. mastoiditis, tonsillitis, otitis media, epiglotitis and sinusitis when accompanied by severe signs and symptoms,? lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar, broncho-pneumonia and community acquired pneumonia,? genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, , female genital infections,? gastrointestinal infections: e.g. intra-abdominal sepsis, peritonitis.,? skin and skin structure infections, in particular cellulitis, animal bites, diabetic foot infections, vascular surgery infection/ischaemic soft tissue infection, severe dental abscess,? other infections e.g. septic abortion, puerperal sepsis, post-surgical infections.,? curam is indicated for prophylaxis against infection in major surgical procedures that may be associated with higher risk of infectious complications eg. gastrointestinal surgery.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - amoxicillin sodium, quantity: 2.12 g (equivalent: amoxicillin, qty 2 g); potassium clavulanate, quantity: 238.3 mg (equivalent: clavulanic acid, qty 200 mg) - injection, powder for - excipient ingredients: - curam is an antibiotic alternative to narrow spectrum and broad-spectrum antibiotics for the treatment of polymicrobial infections; especially in mixed gram negative and gram positive infections, and situations where microbial confirmation has not yet been obtained.,infections caused by amoxicillin susceptible organisms are amenable to curam treatment due to its amoxicillin content.,infections caused by beta-lactamase producing amoxicillin resistant organisms are also amenable to curam due to its clavulanic acid content.,susceptibility to curam will vary with geography and time. local susceptibility data should be consulted where available, and microbiological sampling and susceptibility testing performed where necessary. amoxicillin/clavulanic acid should be used in accordance with local official antibiotic-prescribing guidelines and local susceptibility data.,curam is indicated for the short term treatment of serious bacterial infections such as:,? upper respiratory tract infections (including ent): e.g. mastoiditis, tonsillitis, otitis media, epiglotitis and sinusitis when accompanied by severe signs and symptoms,? lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar, broncho-pneumonia and community acquired pneumonia,? genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections,? gastrointestinal infections e.g. intra-abdominal sepsis, peritonitis.,? skin and skin structure infections, in particular cellulitis, animal bites, diabetic foot infections, vascular surgery infection/ischaemic soft tissue infection, severe dental abscess,? other infections e.g. septic abortion, puerperal sepsis, post-surgical infections.,? curam is indicated for prophylaxis against infection in major surgical procedures that may be associated with higher risk of infectious complications eg. gastrointestinal surgery.

몰타 - 영어 - Medicines Authority

fresenius kabi italia s.r.l via camagre 41, 37063 isola della scala (vr) , italy - poly, hydroxyethyl, starch, potassium chloride, magnesium chloride, hexahydrate, sodium acetate, trihydrate, sodium chloride - solution for infusion - sodium acetate trihydrate 4.63 g sodium chloride 6.02 g magnesium chloride hexahydrate 0.3 g poly(o-2-hydroxyethyl)starch 60 g potassium chloride 0.3 g - blood substitutes and perfusion solutions

나미비아 - 영어 - Namibia Medicines Regulatory Council

adcock ingram critical care (pty) ltd - hydroxyethyl starch; sodium chloride; potassium chloride; calcium chloride dihydrate; magnesium chloride hexahydrate; sodium acetate trihydrate - infusion solution - each 1000ml contains hydroxyethyl starch 60g, sodium chloride 6g, potassium chloride 0.4g, calcium chloride dihydrate 0.134g, ma

사이프러스 - 그리스어 - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

fresenius kabi deutschland gmbh, germany (0000003454) ., bad homburg v.d.h., 61346 - sodium acetate trihydrate; potassium chloride; sodium chloride; magnesium chloride hexahydrate; poly-(0-2-hydroxyethyl)starch (130/0.4) - solution for infusion - 6% - sodium acetate trihydrate (0006131904) 4.63g; potassium chloride (0007447407) 0.3g; sodium chloride (0007647145) 6.02g; magnesium chloride hexahydrate (0007791186) 0.3g; poly-(0-2-hydroxyethyl)starch (130/0.4) (8000002588) 60g - hetastarch